Efficacy and safety of nesiritide in patients with acute decompensated heart failure

References

• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), e25–e146 (2008).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart83(5), 596–602 (2000).
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Wang Y, Mattera JA et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation113(13), 1683–1692 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur. J. Heart. Fail.4(3), 361–371 (2002).
   PubMed Web of Science ®Google Scholar
• Adams KF Jr, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart. J.149(2), 209–216 (2005).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA293(5), 572–580 (2005).
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Brutsaert D, Dickstein K et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur. Heart. J.27(22), 2725–2736 (2006).
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Lichtman JH, Heidenreich PA et al. National trends in outcomes among elderly patients with heart failure. Am. J. Med.119(7), e1–e7 (2006).
   Google Scholar
• Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation113(6), e85–e151 (2006).
   PubMed Web of Science ®Google Scholar
• Jessup M, Abraham WT, Casey DE et al.; 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol.53, 1343–1382 (2009).
   Web of Science ®Google Scholar
• Felker GM, Adams KF Jr, Konstam MA, O’Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am. Heart. J.145(2 Suppl.), S18–S25 (2003).
   PubMed Web of Science ®Google Scholar
• Lucas C, Johnson W, Hamilton MA et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am. Heart. J.140(6), 840–847 (2000).
   PubMed Web of Science ®Google Scholar
• Adamson PB, Magalski A, Braunschweig F et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J. Am. Coll. Cardiol.41(4), 565–571 (2003).
   PubMed Web of Science ®Google Scholar
• Heart Failure Society of America. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J. Card. Fail.12(1), 10–38 (2006).
   PubMed Web of Science ®Google Scholar
• Ramírez A, Abelmann WH. Cardiac decompensation. N. Engl. J. Med.290(9), 499–501 (1974).
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Gattis WA, Uretsky BF et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart. J.138(1 Pt 1), 78–86 (1999).
   PubMed Web of Science ®Google Scholar
• Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and the risk of arrhythmic death in patients with left ventricular dysfunction. Circulation100(12), 1311–1315 (1999).
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA287(12), 1541–1547 (2002).
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Johannes RS, Pine M et al. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure national Registry (ADHERE) database. Am. Heart J.154, 267–277 (2007).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos Get al. European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J.29, 2388–2442 (2008).
   PubMed Web of Science ®Google Scholar
• Natrecor® (nesiritide), prescribing information. Scios, Inc., Fremont, CA, USA (2005).
   Google Scholar
• Takahashi T, Allen PD, Izumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca2+ ATPase gene. Circ. Res.71(1), 9–17 (1992).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yamazaki T, Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc. Res.51(3), 489–494 (2001).
   PubMed Web of Science ®Google Scholar
• Chen HH. Heart Failure. A state of brain natriuretic peptide deficiency or resistance or both. J. Am. Coll. Cardiol.49(10), 1089–1091 (2007).
   PubMed Web of Science ®Google Scholar
• Mills RM, LeJemtel TH, Horton DP et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol.34(1), 155–162 (1999).
   PubMed Web of Science ®Google Scholar
• Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest. Heart Fail.11(1), 30–38 (2005).
   PubMedGoogle Scholar
• Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab.76(1), 91–96 (1993).
   PubMed Web of Science ®Google Scholar
• La Villa G, Fronzaroli C, Lazzeri C et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J. Clin. Endocrinol. Metab.78(5), 1166–1171 (1994).
   PubMed Web of Science ®Google Scholar
• Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin. Sci. (Lond.)96(1), 5–15 (1999).
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusions in patients with congestive heart failure. Circulation84(4), 1581–1588 (1991).
   PubMed Web of Science ®Google Scholar
• Wang DJ, Dowling TC, Meadows D et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation110(12), 1620–1625 (2004).
   PubMed Web of Science ®Google Scholar
• Hobbs RE, Mills RM. Therapeutic potential of nesiritide (recombinant B-type natriuretic peptide) in the treatment of heart failure. Expert Opin. Investig. Drugs8(7), 1063–1072 (1999).
   PubMedGoogle Scholar
• Witteles RM, Kao D, Christopherson D et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol.50(19), 1835–1840 (2007).
   PubMed Web of Science ®Google Scholar
• Butler J, Emerman C, Peacock WF, Mathur VS, Young JB. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol. Dial. Transplant.19(2), 391–399 (2004).
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation111(12), 1487–1491 (2005).
   PubMed Web of Science ®Google Scholar
• Iglesias J, Hom D, Antoniotti M, Ayoub S, Levine JS. Predictors of worsening renal function in adult patients with congestive heart failure receiving recombinant human B-type brain natriuretic peptide (nesiritide). Nephrol. Dial. Transplant.21(12), 3458–3465 (2006).
   PubMed Web of Science ®Google Scholar
• Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med.343(4), 246–253 (2000).
   PubMed Web of Science ®Google Scholar
• Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart. J.144(6), 1102–1108 (2002).
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA287(12), 1531–1540 (2002).
   PubMed Web of Science ®Google Scholar
• Peacock WF IV, Holland R, Gyarmathy R et al. Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J. Emerg. Med.29(3), 243–252 (2005).
   PubMed Web of Science ®Google Scholar
• Peacock WF IV. Initial results from the PROACTION study. J. Emerg. Med.31(4), 435–436 (2006).
   PubMed Web of Science ®Google Scholar
• Yancy CW, Saltzberg MT, Berkowitz RLet al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I Trial). Am. J. Cardiol.94, 595–601 (2004).
   PubMed Web of Science ®Google Scholar
• Yancy CW, Sing A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the follow-up serial infusions of nesiritide [FUSION I] Trial). Am. J. Cardiol.98, 226–229 (2006).
   PubMed Web of Science ®Google Scholar
• Yancy CW, Krum H, Massie BMet al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Results of the second follow-up serial infusions of nesiritide (FUSION II) Trial. Circ. Heart Fail.1, 9–16 (2008).
   PubMed Web of Science ®Google Scholar
• Jefferies JL, Price JF, Denfield SW et al. Safety and efficacy of nesiritide in pediatric heart failure. J. Card. Fail.13(7), 541–548 (2007).
   PubMed Web of Science ®Google Scholar
• Mahle WT, Cuadrado AR, Kirshbom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure. Pediatr. Crit. Care. Med.6(5), 543–546 (2005).
   PubMedGoogle Scholar
• Mentzer RM Jr, Oz MC, Sladen RN et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J. Am. Coll. Cardiol.49(6), 716–726 (2007).
   PubMed Web of Science ®Google Scholar
• Beaver TM, Winterstein AG, Shuster JJ et al. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. Clin. Cardiol.29(1), 18–24 (2006).
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA293(15), 1900–1905 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol.38(4), 955–962 (2001).
   PubMed Web of Science ®Google Scholar
• McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation109(8), 1004–1009 (2004).
   PubMed Web of Science ®Google Scholar
• Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J. Am. Coll. Cardiol.35(3), 681–689 (2000).
   PubMed Web of Science ®Google Scholar
• Scios Inc. Dear Healthcare Provider letter. Panel of Cardiology Experts Provides Recommendations to Scios Regarding NATRECOR®. 13, 1–8 July (2005).
   Google Scholar